巨星醫療(02393.HK)澄清商業糾紛已解決
巨星醫療(02393.HK)公布,公司注意到中國若干媒體上周五(25日)報道公司主席兼行政總裁何震發之關連人士與一名業務夥伴之商業糾紛,及一位前業務夥伴之操守。
公司表示,自公司成立起,有關關連人士並無持有公司任何證券權益,亦無以任何方式參與公司及其附屬公司之業務及策略發展。另外,公司早前亦公布與一名合作夥伴的商業糾紛已圓滿解決。
董事會重申,公司實施審慎的財務管理,擁有充足及健康的現金流,以應付日常業務運作及拓展,並成功自低利潤的非醫療業務改革及轉營為高利潤的醫療業務,亦令公司成為羅氏診斷產品(上海)有限公司於中國的重要合作夥伴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.